# A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

> **NCT04104776** · PHASE1,PHASE2 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 275 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Diffuse Large B Cell Lymphoma
- Lymphoma, T-Cell
- Mesothelioma, Malignant
- Prostatic Neoplasms, Castration-Resistant
- Endometrial Cancer
- Ovarian Clear Cell Carcinoma
- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Tulmimetostat
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT04104776
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-09-18
- **Primary completion:** 2030-02-27
- **Final completion:** 2030-02-27
- **Target enrollment:** 275 (ESTIMATED)
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04104776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04104776, "A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04104776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*